The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
Liver International · 2024
DOI: 10.1111/liv.15897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Hye Won Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Liver Cirrhosis, Elasticity Imaging Techniques, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Research Foundation, Faculty Research Grant of Yonsei University College of Medicine.
Abstract (Originalsprache)
Background
The prognosis of metabolic dysfunction‐associated steatotic liver disease (MASLD) is associated with liver fibrosis. We investigated the associations between changes in liver stiffness measurement (LSM) over 3‐year period and the development of cirrhosis or hepatocellular carcinoma (HCC) in patients with MASLD.
Methods
This study involved patients with MASLD who underwent transient elastography at baseline and 3 years after baseline from 2012 to 2020. Low (L), indeterminate (I) and high (H) LSM values were classified as 12 kPa respectively.
Results
Among 1738 patients, 150 (8.6%) were diagnosed with cirrhosis or HCC. The proportions of patients with L, I and H risk were 69.7%, 19.9% and 10.5% at baseline, and 78.8%, 12.8% and 8.4% at 3 years after baseline, respectively. The incidence rates of cirrhosis or HCC per 1000 person‐years were 3.7 (95% confidence interval [CI], 2.4–5.5) in the L → L + I group, 23.9 (95% CI, 17.1–32.6) in the I → L + I group, 38.3 (95% CI, 22.3–61.3) in the H → L + I group, 62.5 (95% CI, 32.3–109.2) in the I → H group, 67.8 (95% CI, 18.5–173.6) in the L → H group and 93.9 (95% CI 70.1–123.1) in the H → H group. Two risk factors for the development of cirrhosis or HCC were LSM changes and low platelet counts.
Conclusion
LSM changes could predict clinical outcomes in patients with MASLD. Thus, it is important to monitor changes in the fibrotic burden by regular assessment of LSM values.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea.
- Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Hye Won Lee, Sang Hoon Ahn, Jonggi Choi
Förderung
- National Research Foundation
- Faculty Research Grant of Yonsei University College of Medicine
Zitieren
APA
Lee, H. W., Kim, K. H., Ahn, S. H., Lee, H. C., & Choi, J. (2024). The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease. Liver International. https://doi.org/10.1111/liv.15897
Vancouver
Lee HW, Kim KH, Ahn SH, Lee HC, Choi J. The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease. Liver International. 2024. doi:10.1111/liv.15897
BibTeX
@article{Lee2024,
author = {Lee, Hye Won and Kim, Kun Hee and Ahn, Sang Hoon and Lee, Han Chu and Choi, Jonggi},
title = {The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15897}
}
EUVIMED